Adam Gregory joins John Joson Ng on Nucleate Singapore’s Pulse podcast where he highlights success stories from Singapore’s vibrant biotech scene, including Enleofen Bio and Hummingbird Bioscience, and discusses the evolving nature of patent strategies in the face of emerging technologies like AI and gene editing. From understanding the differences between patents, trademarks, and copyrights to exploring the patent application process and common pitfalls, this episode is packed with valuable information for anyone in the biotech industry.
Listen time: 43 minutes
Listen to the podcast here on Spotify or Apple music.
You can view the full podcast transcript here.
Visit our Life Sciences patents page for more information on this topic.
Originally published on the Nucleate Singapore Pulse podcast by John Joson Ng.
Adam is a Partner and Patent Attorney at Mewburn Ellis. He works with biotech companies to build and manage their patent portfolios, drafting patent applications and co-ordinating prosecution worldwide. Adam has particular experience handling portfolios relating to therapeutics (particularly immunotherapies, including adoptive cellular therapies), antibody technology, diagnostics, and regenerative medicine.
Email: adam.gregory@mewburn.com
Our IP specialists work at all stage of the IP life cycle and provide strategic advice about patent, trade mark and registered designs, as well as any IP-related disputes and legal and commercial requirements.
Our peopleWe have an easily-accessible office in central London, as well as a number of regional offices throughout the UK and an office in Munich, Germany. We’d love to hear from you, so please get in touch.
Get in touch